Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

290
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
290
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

264
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
264
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

2.7K
Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
2.7K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

279
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
279
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

245
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
245
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

251
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
251

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gain-of-function PfAAT1 mutations compensate for impaired PfCRT function in <i>Plasmodium falciparum</i>.

Research square·2026
Same author

Close-Shell and Biradical Enantiomers for Probing the Chiral-Induced Spin Selectivity Effect.

The journal of physical chemistry letters·2026
Same author

Dynamic breaking of mirror symmetry in spin-dependent electron transport through chiral media causes enantiomeric excesses.

Science advances·2026
Same author

Evaluation of CT-Guided Pudendal Nerve Cryoneurolysis for the Treatment of Refractory Pelvic Pain.

The American journal of hospice & palliative care·2026
Same author

Designing a Case Management Mobile Health App for Violence Intervention Programs: Mixed Methods Human-Centered Design Study.

JMIR formative research·2026
Same author

Complex mesoscale landscapes beneath Antarctica mapped from space.

Science (New York, N.Y.)·2026

Related Experiment Video

Updated: Oct 26, 2025

Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent
06:46

Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent

Published on: May 8, 2017

8.9K

Indole Inhibitors of MMP-13 for Arthritic Disorders.

Steven J Taylor1, Asitha Abeywardane1, Shuang Liang1

  • 1Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877-0368, United States.

ACS Omega
|August 2, 2021
PubMed
Summary

Selective matrix metalloproteinase-13 (MMP-13) inhibitors were designed for rheumatoid arthritis research. These compounds showed significant reduction in arthritis scores in mice, demonstrating therapeutic potential.

More Related Videos

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

1.3K
The Monoiodoacetate Model of Osteoarthritis Pain in the Mouse
09:26

The Monoiodoacetate Model of Osteoarthritis Pain in the Mouse

Published on: May 16, 2016

36.3K

Related Experiment Videos

Last Updated: Oct 26, 2025

Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent
06:46

Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent

Published on: May 8, 2017

8.9K
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

1.3K
The Monoiodoacetate Model of Osteoarthritis Pain in the Mouse
09:26

The Monoiodoacetate Model of Osteoarthritis Pain in the Mouse

Published on: May 16, 2016

36.3K

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Drug Discovery

Background:

  • Matrix metalloproteinase-13 (MMP-13) plays a role in rheumatoid arthritis pathogenesis.
  • Developing selective MMP-13 inhibitors is a therapeutic strategy for inflammatory joint diseases.

Purpose of the Study:

  • To design and optimize selective MMP-13 inhibitors with favorable potency and physicochemical properties.
  • To evaluate the in vivo efficacy of these inhibitors in a murine model of rheumatoid arthritis.

Main Methods:

  • Fragment merging and multiparameter optimization were employed for inhibitor design.
  • Structure-based insights guided potency optimization by modifying core molecular interactions.
  • Selective MMP-13 inhibitors were tested in a murine model of rheumatoid arthritis over 14 days.

Main Results:

  • Optimized inhibitors exhibited a balance of potency and drug-like physicochemical properties.
  • Introduction of polar interactions enhanced inhibitor potency without compromising physicochemical properties.
  • Treatment with selective MMP-13 inhibitors significantly reduced arthritic scores in mice compared to controls.

Conclusions:

  • The designed selective MMP-13 inhibitors serve as valuable tool compounds for in vivo studies.
  • These inhibitors demonstrate therapeutic potential for managing rheumatoid arthritis.
  • Further development of MMP-13 inhibitors could offer a novel treatment approach for inflammatory arthritis.